Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Ent

Similar documents
CHEMOTHERAPY DEC (NFLX), ofloxacin (OFLX), ciprofloxacin (CPFX) Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterococcus faecali

Key words : 7432-S, Oral cephem, Urinary tract infection Fig. 1. Chemical structure of 7432-S.

Staphylococcus sp. K.pneumoniae P.mirabilis C.freundii E. cloacae Serratia sp. P. aeruginosa ml, Enterococcus avium >100ƒÊg/ml


Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone

epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia

VOL.42 S-1 methicillin-susceptible Staphylococcus aureus (MSSA), Staphylococcus epidermidis, Enterococcus faecalis, Escherichia coli, Klebsiella pneum

CHEMOTHERAPY aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Prote

VOL.35 S-2 CHEMOTHERAPY Table 1 Sex and age distribution Table 2 Applications of treatment with carumonam Table 3 Concentration of carumonam in human

Fig. 1 Chemical structure of DL-8280


Fig. 1 Chemical structure of KW-1070

CHEMOTHERAPY

THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec DNA 2, , % 1.65% 1.17% 90% 9 Escherichia coli -

CHEMOTHERAPY

CHEMOTHERAPY

VOL.42 S-1

CHEMOTHERAPY JUN Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter cloacae 27, Proteus rettgeri 7, Proteus inconstans 20, Proteus

Fig.1 Chemical structure of BAY o 9867


Table1MIC of BAY o 9867 against standard strains

日本化学療法学会雑誌第58巻第4号

VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains )

VOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant St

CHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates

CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study


CHEMOTHERAPY NOV S. aureus, S. epidermidis, E. coli, K. pgeumoniae, E. cloacae, S. marcescens, P. mirabilis, Proteus, P. aeruginosa Inoculum siz


pneumoniae 30, C. freundii 32, E. aerogenes 27, E. cloacae 32, P. mirabilis 31, P. vulgaris 34, M. morganii 32, S. marcescens 31, H. influenzae 27, P.


Table 1 Classification of female patients with vesical irritating symptom by their signs : Urinary pain with or without other vesical irritability. s

coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, F

Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates

THE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterococcus avium 5Š, Corynebacterium xerosis 10Š, Corynebacterium pseudodiphtheriticum 10Š, Corynebacterium

CHEMOTHERAPY

1272 CHEMOTHERAPY MAR. 1975

988 CHEMOTHERAPY NOV. 1971


Fig. 1 Chemical structure of norfioxacin (AM-715)

CHEMOTHERAPY Fig. 1 Chemical structure of CXM-AX

VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity of gram nega



VOL.27 S-5 CHEMOTHERAPY Table 1 Clinical evaluations of cefamandole on UTI (1) Benign prostatic hypertrophy (2) Transurethral resection of bladder tum

CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin

CHEMOTHERAPY Methicillin-resistant S.aureus(MRSA) coccus epidermidis 105 Streptococcus pyogenes E.faecali senterococcus avium Enterococcus faecium Str

semen quality or those without WBC in semen. In the patients with azoospermia and normal FSH levels (normogonadotropic azzospermia), the antibody (IgG

CHEMOTHERAPY JUNE 1987 Table1 Media used *BHIB, brain heart infusion broth (Difco); /3 -NAD, S -nicotinamidoadeninedinucleotide (Sigma Chemical Co.);

Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile

日本化学療法学会雑誌第61巻第6号

VOL.48 NO.7 lase negative staphylococci, Escherichia coli, Klebsiella spp., Citrobacter freundii, Enterobacter spp., indole-positive Proteus, Serratia


VOL.30 S-1 CHEMOTHERAPY Table 1 Antibacterial activity of CTT against standard strains Table 2 Antibacterial activity of CTT against standard strains

Fig. 1 Chemical structure of TE-031 Code number: TE-031 Chemical name: (-) (3R, 4S, 5S, 6R, 7R, 9R, 11R, 12R, 13S, 14R)-4-[(2, 6-dideoxy-3-C-methyl-3-


VOL. 43 NO. 4

04-c-„FŒ{›xŒ¾-4.01

- 1 -



VOL. 34 S-2 CHEMOTH8RAPY 913


CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Kle


CHEMOTHERAPY JAN Fig. 1 Structure of cephradine

CHEMOTHERAPY APRIL 1992 Acinetobacter calcoaceticus Staphylococcus aureus, Escherichia coli P. aeruginosa E. eoli, Klebsiella pneumoniae Serratia marc

VOL.27 S-3 CHEMO THERAPY mido)-3-[[[1- (2-dimethylaminoethyl)-1H-tetrazol-5-yl] -thio] methyl]-ceph-3-em-4-carboxylic acid dihydro- S. aureus 209-P JC

Title 外傷性脊髄損傷患者の泌尿器科学的研究第 3 報 : 上部尿路のレ線学的研究並びに腎機能について Author(s) 伊藤, 順勉 Citation 泌尿器科紀要 (1965), 11(4): Issue Date URL

Streptococcus pneumoniae,streptococcus pyogenes,streptococcus agalactiae,neisseria gonorrhoeae,h.influenzae,moraxella subgenus Branhamella catarrharis

CHEMO THE RAPY OCT. 1994

2108 CHEMOTHERAPY SEPT Table 1 Antimicrobial spectrum Fig. 1

CHEMOTHERAPY DEC Table 1 Antibacterial spectra of T-1982, CTT, CMZ, CTX, CPZ and CEZ 106 CFU/ml Note: P; Peptococcus, S; Streptococcus, G; Gaffk

Fig. 1 Clinical findings and extent of inflammation area in female urethrocystitis Fig. 2 Classification and distribution of female patients with blad

CHEMOTHERAPY MAY. 1988

Key words: Disinfectants, Gram negative rods, Bactericidal effect P. aeruginosa 1, P. fluorescens 20 P. putida 179, P. cepacia 216 P. maltophilia 227,

CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels of mezlocillin

VOL.47 NO.5 Table 1. Susceptibility distribution of Ĉ- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus

Hisao Takayasu Department of Urology, Faculty of Medicine, University of Tokyo Masaaki Ohkoshi Department of Urology, Tokai University School of Medic



Title 尿路感染症分離菌の年次的変遷と薬剤感受性の検討 ( ニューキノロン系を中心として ) 深津, 英捷 ; 本多, 靖明 ; 水本, 裕之 ; 瀧, 知弘 ; 三井, Author(s) 々村, 仁志 ; 羽田野, 幸夫 ; 平岩, 親輔 ; 吉川, 和宏 ; 山田彰 ; 瀬川, 昭夫 Ci

PCG = Benzylpenicillin ABPC= Ampicillin AMPC= Amoxicillin MPIPC = Oxacillin MCIPC = Cloxacillin SBPC= Sulbenicillin PIPC= Piperacillin

THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec LVFX 100 mg 3 / mg 2 / LVFX PK PD mg mg 1 1 AUC/MIC

VOL. 23 NO. 3 CHEMOTHERAPY 1379 Table 1 Susceptibility of clinical isolated strains to Tobramycin

日本化学療法学会雑誌第64巻第4号


co Kanamycin (KM), Streptomycin (SM), Fradiomycin Table 2. Comparison of antibacterial activity of 3', 4'-dideoxykanamycin B with that of other antibi


Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII (45)

02-(a)-Łi’ì™·Łv-4.11


CHEMOTHERAPY DEC phvlococcus aureus Staphylococcus Enterococcus faecalis Escherichia Klebsiella pneumoniae Serratia marcescens Pseudomonas cepac


Key words: E. coli O 157: H7, fosfomycin, verotoxin, mouse infection

CHEMOTHERAPY Fig. 1 Body weight changes of pregnant mice treated orally with AM- 715 Day of sestation

Key words: Antibodies to Leptospira, Tokyo, Uveitis

CHEMOTHERAPY APR Fig. 2 The inactivation of aminoglycoside antibiotics by PC-904 Fig. 3 Serum concentration of PC-904 (1) Fig. 4 Urinary recover

03-b-„FŒ{›xŒ¾-4.02

Key words: Norfloxacin (NFLX), Infectious enteritis, Double-blind method

Transcription:

Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Enterococcus faecalis

Klebsiella pneumoniae, Morganella morganii, Serratia marcescens

Fig. 7. Sensitivity distribution of clinical isolates Fig. 8. Sensitivity distribution of clinical isolates

Table 4. Overall clinical efficacy of NY-198 by Dr's evaluation Table 5. Overall clinical efficacy of NY-198 in acute uncomplicated cystitis Table 6. Overall clinical efficacy of NY-198 in complicated UTI

Table 7. Overall clinical efficacy of NY-198 in complicated UTI 400mg/day treatment Table 8. Overall clinical efficacy of NY-198 in complicated UTI 600mg/day treatment Table 9. Overall clinical efficacy of NY-198 classified by the type of infection

Table 10. Overall clinical efficacy of NY-198 classified by the type of infection 400mg/day Table 11. Overall clinical efficacy of NY-198 classified by the type of infection 600mg/day Table 12. Bacteriological response to NY-198 in acute uncomplicated cystitis Table 13. Strains* appearing after NY-198 treatment in acute uncomplicated cystitis * Persisted: Regardless of bacterial couni * Regardless of bacterial count

Table 14. Relation between MIC and bacteriological response to NY-198 treatment in uncomplicated cystitis No. of strains eradicated/no. of strains isolated Table 15. Bacteriological response to NY-198 in complicated UTI Table 16. Strains* appearing after NY-198 treatment in complicated UTI * Regardless of bacterial count * Persisted: Regardless of bacterial count

Table 17. Relation between MIC and bacteriological response to NY-198 treatment in complicated UTI No. of strains eradicated/no. of strains isolated

Table 18. Incidence of clinical adverse reactions No. of patients with adverse reactions / Total No. of patients evaluated of adverse reaction necessary to discontinue for adverse reaction was necessary for adverse reaction was not necessary Total No. of patients with adverse reactions / Total No. of patients evaluated

Table 19. Changes in laboratory test results

FUNDAMENTAL AND CLINICAL STUDIES ON NY-198 IN THE UROLOGICAL FIELD YOSHITSUGU NASU, MASAHIKO TSUGAWA, MIKI0 KISHI, AKIHIRO MIZUNO, HIROMI KUMON and HIROYUKI OHMORI Department of Urology (Director: Prof. H. OHmoRi), Medical School, Okayama University, Okayama ATSUSHI SONE, MANABU SUZUKI, MASAMICHI AMANO and HIROYOSHI TANAKA Department of Urology (Director: Prof. H. TANAKA), Kawasaki Medical University, Kurashiki MOTOYOSHI TAKADA Department of Urology, Kawasaki Hospital, Kawasaki Medical University, Okayama KATSUYOSHI KONDO and ATSUSHI KONDO Department of Urology, Okayama Red Cross Hospital, Okayama KATSUICHI NANBA Department of Urology, Okayama Municipal Hospital, Okayama Department Department Department TSUYOSHI SHIRAGA of Urology, Okayama Saiseikai Hospital, Okayama YASUHIRO KATAYAMA of Urology, Tamano City Hospital, Tamano TERUAKI AKAEDA of Urology, Tsuyama Central Hospital, Tsuyama HITOSHI TAKAMOTO Department of Urology, Kasaoka City Hospital, Kasaoka Department NOBUYUKI AKAZAWA of Urology, Onomichi City Hospital, Onomichi YOSHIKAZU HIRAI and YASUHIRO KANEMASA Department of Bacteriology (Director: Prof. Y. KANEMASA), Medical School, Okayama University, Okayama We studied NY-198, a new orally active antimicrobial agent, fundamentally and clinically in the urological field. 1) NY-198 showed broad and potent antibacterial activity. It inhibited Gram-positive bacteria including Enterococcus faecalis, and Gram-negative bacteria including Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Proteus vulgaris, Serratia marcescens and Pseudomonas aeruginosa. 2) All of 33 patients with acute uncomplicated cystitis showed excellent or good response to NY-198 treatment. Thirty-eight of 59 patients with chronic complicated UTI also showed excellent or good response. 3) Side-effects were observed in three patients, who complained of gastro-intestinal disturbance. These symptoms disappeared soon after cessation of treatment of NY-198. Abnormal laboratory findings were noted in eight instances from six patients, but were mild and transient.

2024 © docsplayer.net プライバシー | 利用規約 | フィードバック